Gilead Sciences to buy all rights of GS-1811 from Jounce
Pharmaceutical Technology
DECEMBER 28, 2022
Gilead Sciences and Jounce Therapeutics have amended their current license agreement for first-in-class immunotherapy, GS-1811 (formerly JTX-1811). The initial license agreement was signed in 2020. The amended agreement will allow Gilead Sciences to acquire all the remaining rights for GS-1811 from Jounce Therapeutics. Certain operational obligations of the companies that are related to GS-1811 have also been terminated as part of the transaction.
Let's personalize your content